2021

MAR.

Received official notification from USFDA that invites BoYen Therapeutics to submit IND for BY-101, for phase 2B clinical trials.

FEB.

Entered into agreement with Taipei World Trade Center International Trade Building, BoYen Therapeutics will relocate to its new premise in May.

JAN.

Contract signed between BoYen Therapeutics and the National Health Research Institutes for BY-102.

2020

NOV.

Welcome M. Sherry Ku PhD on board as part of our medical consultant team to assist in the development of drug projects BY-101and BY-102.

Patents approved by the United States Patent and Trademark Office for BY-102 structural patents and dosage form, this opens the door for the vast market in the treatment of multiple sclerosis.

OCT.

Signed a collaboration/supply agreement with ScinoPharm Taiwan, Ltd, for clinical experimental drugs SPT8278 / BY-101.

SEP.

FDA recommends a small-scale randomized Phase IIB/III clinical trial for BY-101.

JUL.

Completed BY-101 Written-Response-Only Pre-IND meeting with FDA.

JUN.

Awards Bestat Pharmaservices BY-101 clinical protocol contract.

2019

NOV.

Completed a Face-to-Face Pre-IND meeting with FDA for BY-101.

JAN.

BY-101 acquired Orphan Drug Designation form FDA.

2017

OCT.

New anti-cancer prodrug (BYT-3156) approved by the European Patent Office.

JAN.

New anti-cancer prodrug (BYT-3156) approved by the United States Patent Office.

2015

JAN

Approved and designated by the Industrial Development Bureau, MOEA(IDB) as a Biotechnology New Drug Company.

2014

MAY.

SBIR Phase 2 approved by the Ministry of Economic Affairs.

2013

AUG.

SBIR Phase1 approved by the Ministry of Economic Affairs.

2012

AUG.

Laboratory relocates to the Drug Research Center of National Taiwan University, College of Medicine.

2010

OCT.

Laboratory set up the Institute of Chemistry, Academia Sinica.

JUN.

BoYen Therapeutics Inc. established in Taipei, Taiwan.